{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:23:22Z","timestamp":1792268602851,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T00:00:00Z","timestamp":1516147200000},"content-version":"vor","delay-in-days":381,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jacc.2016.10.057","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T18:17:17Z","timestamp":1483985837000},"page":"147-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"title":["Oxidized Phospholipids on Apolipoprotein\u00a0B-100 and Recurrent\u00a0Ischemic Events Following Stroke or Transient Ischemic Attack"],"prefix":"10.1016","volume":"69","author":[{"given":"Young Sup","family":"Byun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihang","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"DeMicco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Laskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L.","family":"Witztum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2016.10.057_bib1","first-page":"e38","article-title":"Heart disease and stroke statistics\u20142016 update: a report from the American Heart Association","volume":"133","author":"Mozaffarian","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.057_bib2","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1161\/CIRCULATIONAHA.111.018820","article-title":"Global variation in the relative burden of stroke and ischemic heart disease\/clinical perspective","volume":"124","author":"Kim","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.057_bib3","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1194\/jlr.M040733","article-title":"Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)","volume":"54","author":"Leibundgut","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib4","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1161\/CIRCRESAHA.110.223875","article-title":"Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity","volume":"108","author":"Miller","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1146\/annurev-pathol-020712-163936","article-title":"The influence of innate and adaptive immune responses on atherosclerosis","volume":"9","author":"Witztum","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.jacc.2016.10.057_bib6","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1194\/jlr.P030890","article-title":"Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions","volume":"53","author":"van Dijk","year":"2012","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib7","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.jacc.2014.01.055","article-title":"Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans","volume":"63","author":"Ravandi","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"Suppl","key":"10.1016\/j.jacc.2016.10.057_bib8","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1194\/jlr.R800074-JLR200","article-title":"The role of oxidized phospholipids in atherosclerosis","volume":"50","author":"Berliner","year":"2009","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib9","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.freeradbiomed.2011.08.026","article-title":"Oxidized phospholipid-induced inflammation is mediated by Toll-like receptor 2","volume":"51","author":"Kadl","year":"2011","journal-title":"Free Rad Biol Med"},{"key":"10.1016\/j.jacc.2016.10.057_bib10","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jacc.2011.07.017","article-title":"Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression","volume":"58","author":"Tsimikas","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib11","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1194\/jlr.M400467-JLR200","article-title":"High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins","volume":"46","author":"Schneider","year":"2005","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib12","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1016\/j.jacc.2005.12.047","article-title":"Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin","volume":"47","author":"Rodenburg","year":"2006","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib13","doi-asserted-by":"crossref","first-page":"32343","DOI":"10.1074\/jbc.M110.137257","article-title":"Oxidized cholesteryl esters and phospholipids in zebrafish larvae fed a high cholesterol diet: macrophage binding and activation","volume":"285","author":"Fang","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2016.10.057_bib14","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1016\/j.jacc.2012.08.979","article-title":"Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events","volume":"60","author":"Tsimikas","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib15","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1016\/j.jacc.2013.12.030","article-title":"Pro-inflammatory interleukin-1 genotypes potentiate the risk of coronary artery disease and cardiovascular events mediated by oxidized phospholipids and lipoprotein(a)","volume":"63","author":"Tsimikas","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib16","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jacc.2015.01.050","article-title":"Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial","volume":"65","author":"Byun","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa061894","article-title":"High-dose atorvastatin after stroke or transient ischemic attack","volume":"355","author":"Amarenco","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2016.10.057_bib18","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.057_bib19","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib20","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1194\/jlr.M800174-JLR200","article-title":"A\u00a0novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma","volume":"49","author":"Bergmark","year":"2008","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib21","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1194\/jlr.M036343","article-title":"MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma","volume":"54","author":"Wiesner","year":"2013","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib22","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1194\/jlr.M060210","article-title":"Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a)","volume":"56","author":"Scipione","year":"2015","journal-title":"J\u00a0Lipid Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib23","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/j.jacc.2007.02.052","article-title":"C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus","volume":"49","author":"Ridker","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib24","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1161\/STROKEAHA.107.513259","article-title":"Lipoprotein-associated phospholipase A2 and high-sensitivity C-reactive protein improve the stratification of ischemic stroke risk in the Atherosclerosis Risk In Communities (ARIC) study","volume":"40","author":"Nambi","year":"2009","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2016.10.057_bib25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0021-9150(98)00032-X","article-title":"Atorvastatin and gemfibrozil metabolites, but not the parent drugs, are potent antioxidants against lipoprotein oxidation","volume":"138","author":"Aviram","year":"1998","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2016.10.057_bib26","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1074\/jbc.M513000200","article-title":"Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism","volume":"281","author":"Mason","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jacc.2016.10.057_bib27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2009.05.028","article-title":"Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial","volume":"54","author":"Di Sciascio","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1161\/ATVBAHA.107.145805","article-title":"Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study","volume":"27","author":"Kiechl","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2016.10.057_bib29","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jacl.2016.01.005","article-title":"Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a)","volume":"10","author":"Yeang","year":"2016","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacc.2016.10.057_bib30","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib31","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pcad.2016.07.005","article-title":"The re-emergence of lipoprotein(a) in a broader clinical arena","volume":"59","author":"Tsimikas","year":"2016","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.jacc.2016.10.057_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","article-title":"Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study","volume":"52","author":"Berg","year":"1997","journal-title":"Clin Genet"},{"key":"10.1016\/j.jacc.2016.10.057_bib33","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.057_bib34","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib35","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2016.10.057_bib36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S0735-1097(02)02769-9","article-title":"Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes","volume":"41","author":"Tsimikas","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib37","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1161\/01.CIR.0000141728.23033.B5","article-title":"High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial","volume":"110","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.057_bib38","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1161\/01.CIR.0000130844.01174.55","article-title":"Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein","volume":"109","author":"Tsimikas","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2016.10.057_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.carrev.2011.08.001","article-title":"The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization","volume":"13","author":"Fefer","year":"2012","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.jacc.2016.10.057_bib40","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.coph.2013.02.005","article-title":"Oxidation-specific epitopes and immunological responses: translational biotheranostic implications for atherosclerosis","volume":"13","author":"Leibundgut","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jacc.2016.10.057_bib41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s12265-014-9590-4","article-title":"Imaging of oxidation-specific epitopes with targeted nanoparticles to detect high-risk atherosclerotic lesions: progress and future directions","volume":"7","author":"Briley-Saebo","year":"2014","journal-title":"J\u00a0Cardiovasc Transl Res"},{"key":"10.1016\/j.jacc.2016.10.057_bib42","doi-asserted-by":"crossref","first-page":"4861","DOI":"10.1172\/JCI57755","article-title":"In\u00a0vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish","volume":"121","author":"Fang","year":"2011","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jacc.2016.10.057_bib43","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.jacc.2009.02.041","volume":"53","author":"Fraley","year":"2009","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2016.10.057_bib44","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1210\/jc.2015-1096","article-title":"Elevated lipoprotein(a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100,578 individuals from the general population","volume":"100","author":"Langsted","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716370292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109716370292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:12:08Z","timestamp":1760015528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109716370292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0735109716370292"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2016.10.057","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oxidized Phospholipids on Apolipoprotein\u00a0B-100 and Recurrent\u00a0Ischemic Events Following Stroke or Transient Ischemic Attack","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2016.10.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}